MentalHealth.com Acquires Online Mental Health Platform and Community
SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2024 / Leading patient-first health technology company MentalHealth.com is pleased to announce...
SAN FRANCISCO, CA / ACCESSWIRE / January 8, 2024 / Leading patient-first health technology company MentalHealth.com is pleased to announce...
MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology...
Lykos Therapeutics, formerly known as MAPS PBC, announced the close of Series A financing to support regulatory and pre-launch activities...
Company Also Expects Fourth Quarter 2023 Revenue Above Guidance, Announces General Availability of Augmedix GoSAN FRANCISCO, Jan. 05, 2024 (GLOBE...
Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approvedLONDON, Jan. 05,...
HeartRisk™ Empowers Employers Who Adopt Cardio Diagnostics’ Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and Mitigate Business RisksCHICAGO--(BUSINESS...
NCQA Welcomes Health Care Leaders Dr. Asaf Bitton of Brigham and Women's Hospital and the Harvard T.H. Chan School of...
NORTHAMPTON, MA / ACCESSWIRE / January 4, 2024 / Quest Diagnostics recently provided no-cost Blueprint for Wellness® testing to more...
BRENTWOOD, TN / ACCESSWIRE / January 4, 2024 / Odyssey Behavioral Healthcare, a leading provider of mental health, addiction, and...
New patent issued for core rare disease target indication for crofelemerJaguar is supporting investigator-initiated proof-of-concept studies of crofelemer for the...
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has...
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the...
EMP-01 (R-MDMA) was generally well-tolerated and treatment-related adverse events (AEs) were as expectedThe PK profile of EMP-01 was dose-proportional, and...
Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment...
VILNIUS, LITHUANIA / ACCESSWIRE / December 20, 2023 / From developing healthcare systems to personalized fitness apps such as Joggo,...
VANCOUVER, BC / ACCESSWIRE / December 20, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), Chief Executive Officer...
Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents...
BETHESDA, MD / ACCESSWIRE / December 19, 2023 / Get Well, the global leader in consumer digital patient engagement, announced...
TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider...
BURLINGTON, Mass. and JERUSALEM, Dec. 19, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...